Clinical and translational science
Cure8 research brief
Why This Matters
Pregnant people with Crohn’s disease are often prescribed disease‑modifying therapies, yet clinical trial data in pregnancy are limited. Understanding real‑world medication use and potential drug–drug interactions helps patients and clinicians weigh treatment choices during pregnancy.
Who Should Pay Attention
Pregnant patients with Crohn’s disease or MS; gastroenterologists and obstetricians; pharmacists; researchers in maternal pharmacology.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study used a large US health‑plan claims database (IQVIA PharMetrics Plus) to examine real‑world medication use in people with Crohn’s disease (CD) and multiple sclerosis (MS) who were pregnant between 2021–2024.
The authors report that many pregnant people with CD continued disease‑modifying therapies (DMTs) during pregnancy; nearly half of the CD cohort had DMT exposure, and among those, monoclonal antibodies such as adalimumab and ustekinumab were commonly used.
The analysis also looked for potential drug–drug interactions (DDIs) by focusing on major metabolic and efflux pathways (CYP3A4, P‑gp, BCRP) and found that several concomitant medications during pregnancy may interact with these pathways.
The study highlights complexity of medication regimens in pregnancy and the gap in clinical trial data for pregnant people. This brief summarizes the article’s abstract-level findings (structured content depth: abstract) and does not represent a full review of the underlying data or methods. It does not provide clinical recommendations.
Keep In Mind
Findings come from a health‑plan claims database (IQVIA PharMetrics Plus) covering 2021–2024 and analyze exposure and potential DDI pathways (CYP3A4, P‑gp, BCRP). This is observational claims data reflecting prescriptions/dispensing and potential interaction pathways—not measured drug levels or pregnancy outcomes.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationClinical and translational science
AuthorsWilliams J, Sane R, Joshi A +2 more
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedAug 1, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Real-world patterns of inflammatory bowel disease treatment across adult and pediatric populations: a nationwide cohort study in South Korea
Patients, families, and clinicians may care because the study shows pediatric-onset IBD is more often Crohn's and that children begin advanced therapies earlier than adults. The adult persistence data for vedolizumab and...
GLP-1 receptor agonists and clinical outcomes in adults with Crohn's disease and obesity
This large real-world study suggests GLP-1 receptor agonists used in adults with Crohn’s disease and obesity were associated with lower healthcare use and lower subsequent TNF inhibitor use at 1 and 5 years, findings...
Inflammatory Bowel Disease Treatment Trends and Outcomes in Newly Diagnosed Adults
Earlier use of advanced therapies and less steroid exposure could affect long-term outcomes and side-effect risk for people with newly diagnosed IBD. The study also identifies lower use of advanced therapies among...